MX337035B - Composiciones y metodos para tratar las condiciones producidas por linfopoyetina estromatica timica (tslp). - Google Patents

Composiciones y metodos para tratar las condiciones producidas por linfopoyetina estromatica timica (tslp).

Info

Publication number
MX337035B
MX337035B MX2011004235A MX2011004235A MX337035B MX 337035 B MX337035 B MX 337035B MX 2011004235 A MX2011004235 A MX 2011004235A MX 2011004235 A MX2011004235 A MX 2011004235A MX 337035 B MX337035 B MX 337035B
Authority
MX
Mexico
Prior art keywords
mediated
tslp
treating
tslpr
disease
Prior art date
Application number
MX2011004235A
Other languages
English (en)
Other versions
MX2011004235A (es
Inventor
Anthony B Wood
Richard L Watson
Gregory J Archambeau
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of MX2011004235A publication Critical patent/MX2011004235A/es
Publication of MX337035B publication Critical patent/MX337035B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de una afección o enfermedad mediada por la TSLP o TSLPR, que comprende la administración de un fluido acuoso alterado electrocinéticamente que comprende una solución acuosa iónica de nanoestructuras que contienen oxígeno estabilizado por carga, que tienen sustancialmente un diámetro promedio menor de aproximadamente 100 nanómetros y que se configuran establemente en el fluido acuoso iónico en una cantidad suficiente para tratar una afección o enfermedad mediada por la TSLP o TSLPR. Las nanoestructuras que contienen oxígeno estabilizado por carga se configuran preferentemente de forma estable en el fluido en una cantidad suficiente para proporcionar la modulación del potencial y/o conductividad de la membrana celular. Algunos aspectos que comprenden la modulación o regulación descendente de la expresión y/o actividad de TSLP tienen utilidad para tratar las enfermedades o afecciones mediadas por la TSLP o mediadas por TSLPR, como se describe en la presente (por ejemplo, trastornos del sistema inmune, inflamación alérgica, inflamación alérgica de las vías respiratorias, respuestas inflamatorias Th2 mediada por las DC, dermatitis atópica, eczema atópico, asma, enfermedad obstructiva de las vías respiratorias, enfermedad pulmonar obstructiva crónica, y alergias a los alimentos, artritis inflamatoria, artritis reumatoide, psoriasis, trastornos mediados por IgE, y rino-conjuntivitis.).
MX2011004235A 2008-10-22 2009-10-22 Composiciones y metodos para tratar las condiciones producidas por linfopoyetina estromatica timica (tslp). MX337035B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10748008P 2008-10-22 2008-10-22
US10745308P 2008-10-22 2008-10-22
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061710 WO2010048425A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions

Publications (2)

Publication Number Publication Date
MX2011004235A MX2011004235A (es) 2011-06-24
MX337035B true MX337035B (es) 2016-02-09

Family

ID=42119683

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011004235A MX337035B (es) 2008-10-22 2009-10-22 Composiciones y metodos para tratar las condiciones producidas por linfopoyetina estromatica timica (tslp).
MX2011004233A MX2011004233A (es) 2008-10-22 2009-10-22 Composiciones y metodos para tratar las condiciones producidas por la matriz-metaloproteinasa 9 (mmp9).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011004233A MX2011004233A (es) 2008-10-22 2009-10-22 Composiciones y metodos para tratar las condiciones producidas por la matriz-metaloproteinasa 9 (mmp9).

Country Status (9)

Country Link
EP (2) EP2350263A4 (es)
JP (4) JP5688370B2 (es)
CN (2) CN102256607B (es)
AU (2) AU2009308362B2 (es)
BR (2) BRPI0920201A2 (es)
CA (2) CA2741341A1 (es)
IL (2) IL212277A0 (es)
MX (2) MX337035B (es)
WO (2) WO2010048425A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
WO2008052145A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
CN102076326B (zh) * 2008-04-28 2015-12-02 利发利希奥公司 治疗多发性硬化的组合物和方法
JP5901291B2 (ja) 2008-05-01 2016-04-06 リバルシオ コーポレイション 消化器障害を治療するための組成物および方法
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
AU2011249856B2 (en) 2010-05-07 2015-11-26 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
EP2603202A4 (en) 2010-08-12 2016-06-01 Revalesio Corp COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
CN103561722A (zh) * 2011-04-13 2014-02-05 利发利希奥公司 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法
CN102268069B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂4及其应用
CN102250213B (zh) * 2011-07-01 2012-11-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
KR101492435B1 (ko) * 2012-12-28 2015-02-10 고려대학교 산학협력단 ＨＩＦ­１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
US11345758B2 (en) 2017-06-27 2022-05-31 Translational Sciences, Inc. Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
US20220233641A1 (en) * 2019-05-17 2022-07-28 The Trustees Of The University Of Pennsylvania Methods and Compositions for Treating Obesity and/or Skin Disorders
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289817T3 (es) * 1998-07-28 2008-02-01 The Regents Of The University Of California Acidos nucleicos que codifican un receptor acoplado a proteinas e implicado en la transduccion sensorial.
CN101850120A (zh) * 1999-07-21 2010-10-06 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
EP1599165A4 (en) * 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (ko) * 2004-03-08 2006-05-24 양경숙 차륜 가변형 스쿠터
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080050452A1 (en) * 2006-06-30 2008-02-28 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2086668B1 (en) * 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
CA2667614A1 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
CN102076326B (zh) * 2008-04-28 2015-12-02 利发利希奥公司 治疗多发性硬化的组合物和方法

Also Published As

Publication number Publication date
JP5688371B2 (ja) 2015-03-25
AU2009308302A1 (en) 2010-04-29
EP2350263A4 (en) 2013-07-03
AU2009308302B2 (en) 2016-01-21
JP2012506451A (ja) 2012-03-15
MX2011004233A (es) 2011-06-24
JP5688370B2 (ja) 2015-03-25
AU2009308362B2 (en) 2016-02-04
MX2011004235A (es) 2011-06-24
IL212277A0 (en) 2011-06-30
BRPI0920201A2 (pt) 2019-09-10
CN102257130B (zh) 2016-07-06
CN102256607B (zh) 2014-11-05
CA2741341A1 (en) 2010-04-29
EP2364154A1 (en) 2011-09-14
JP2015044868A (ja) 2015-03-12
WO2010048455A1 (en) 2010-04-29
JP2015044869A (ja) 2015-03-12
IL212309A0 (en) 2011-06-30
JP2012506453A (ja) 2012-03-15
EP2364154A4 (en) 2013-07-10
EP2350263A1 (en) 2011-08-03
WO2010048425A1 (en) 2010-04-29
CN102257130A (zh) 2011-11-23
BRPI0920430A2 (pt) 2019-09-24
CA2741336A1 (en) 2010-04-29
AU2009308362A1 (en) 2010-04-29
IL212309A (en) 2016-04-21
CN102256607A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
MX337035B (es) Composiciones y metodos para tratar las condiciones producidas por linfopoyetina estromatica timica (tslp).
WO2012047733A3 (en) Treatment of acne by conditioned media
WO2010121074A8 (en) Modulation of inflammatory responses by factor xi
PH12014501175B1 (en) Medium composition for rejuvenating stem cells
WO2016144139A3 (ko) 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
AU2012327781B2 (en) Modified Y zeolite, method for preparing same, and use thereof
BR112015015714A2 (pt) suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
EA200802417A1 (ru) Замещенные фенилуксусные кислоты как dp-2-антагонисты
WO2014066468A8 (en) Stable, low viscosity antibody formulation
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
WO2011047345A3 (en) Methods of treating diseases of conditions using mesenchymal stem cells
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
TNSN08333A1 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
NZ599921A (en) Wheelchair
EP3269803A3 (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
MX2016006503A (es) Formulacion de bifidobacterium lactis ncc 2818 tratada con calor que reduce las manifestaciones alergicas.
Fang et al. Bifidobacterium affected the correlation between gut microbial composition, SCFA metabolism, and immunity in mice with DNFB-induced atopic dermatitis
UA101035C2 (ru) Смягчающая композиция на основе вазелина, глицерина и вазелинового масла
WO2013067076A3 (en) Methods and compositions for neuroprotection
NZ598833A (en) Antimicrobial and wound-healing action pharmaceutical composition for external application process of producing the same
MX2010008685A (es) Farmacoforos duales-antagonistas muscarinicos de pde4.
GR1008378B (el) Λειτουργικες επιτραπεζιες ελιες ζυμωμενες με γαλακτικα βακτηρια που διαθετουν προβιοτικες ιδιοτητες
MX2015007855A (es) Dispersiones acuosas de amidas grasas.
CN103655323A (zh) 一种透明质酸修护乳
Cameron et al. Why Do Dominant Personalities Attain Influence in Face-to-Face Groups? The Competence-Signaling Effects of Trait Dominance

Legal Events

Date Code Title Description
FG Grant or registration